Skip to main navigation Skip to search Skip to main content

Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: Design of a longitudinal clinical study

  • Jill E. Lavigne
  • , William T. Shearer
  • , Bruce Thompson
  • , E. John Orav
  • , Thomas J. Starc
  • , Steven D. Colan
  • , Ricardo Pignatelli
  • , Sharon E. O'Brien
  • , Louis Bezold
  • , Phillip LaRusa
  • , Kirk A. Easley
  • , Irene Cheng
  • , Sarah A. Duffy
  • , Steven E. Lipshultz
  • University of Rochester
  • Texas Children's Hospital Houston
  • Clinical Trials and Surveys Corporation
  • Brigham and Women’s Hospital
  • Columbia University
  • Boston Children's Hospital
  • Boston University
  • University of Miami

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Seroreverters (uninfected children of HIV-infected mothers) have exhibited left ventricular (LV) dysfunction. Mitochondrial toxicity associated with in utero of postnatal exposure to highly active antiretroviral therapy (HAART) is a possible mechanism. Adult and animal models have demonstrated associations between LV abnormalities, cardiomyopathy, and components of HAART. Yet, outcomes in children are poorly understood. In this study, we explore HAART-associated LV abnormalities in seroreverters exposed to HAART (n = 144) or never exposed (n = 252). Subjects are drawn from the Women and Infants Transmission Study and the Pediatric Pulmonary and Cardiovascular Complications of HIV Study, respectively. Data include (1) echocardiographic studies of LV structure and function and (2) serologic cardiac biomarkers (cardiac troponin, probrain natriuretic peptide, high-sensitivity C reactive protein), both collected during the first month of life, and again at 6, 12, 24, 36, and 48 months postnatally. Planned analyses include several regression models. At this time, we have access to data for all 252 unexposed children, and 53 exposed subjects are enrolled. The cohorts are similar in terms of gender and race and the recruited subjects are representative of all eligible subjects in terms of exposure to HAART. Recruitment will continue into 2006.

Original languageEnglish
Pages (from-to)187-197
Number of pages11
JournalCardiovascular Toxicology
Volume4
Issue number2
DOIs
StatePublished - 2004

Keywords

  • Antiretroviral therapy
  • Cardiovascular
  • Highly active antiretroviral therapy
  • HIV
  • Mitochondria
  • Prophylaxis
  • Seroreverter
  • Study design
  • Toxicity
  • Vertical transmission

Fingerprint

Dive into the research topics of 'Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: Design of a longitudinal clinical study'. Together they form a unique fingerprint.

Cite this